The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 28, 2017
Filed:
Dec. 15, 2014
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Joseph Kozlowski, Rahway, NJ (US);
Craig Coburn, San Rafael, CA (US);
Wensheng Yu, Rahway, NJ (US);
Ling Tong, Rahway, NJ (US);
Bin HU, Shanghai, CN;
Bin Zhong, Shanghai, CN;
Jinglai Hao, Shanghai, CN;
Dahai Wang, Shanghai, CN;
Tao Ji, Shanghai, CN;
Joseph Kozlowski, Princeton, NJ (US);
Craig Coburn, Novato, CA (US);
Wensheng Yu, Edison, NJ (US);
Ling Tong, Warren, NJ (US);
Bin Hu, Shanghai, CN;
Bin Zhong, Shanghai, CN;
Jinglai Hao, Shanghai, CN;
Dahai Wang, Shanghai, CN;
Tao Ji, Shanghai, CN;
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abstract
The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A', R, R, R, R, R, and Rare defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.